Avergen Pharmaceuticals
New Aggregation Inhibitor for Huntington Disease
APG has identified a new way of preventing aggregation and seeding of mutated huntingtin. The drug candidate is a small molecule, which may be applied orally.
Recently, we could demonstrate that our lead compound improves significantly motor symptoms in a rodent model of Huntington Disease.
Conferences
We presented at BioEurope on November 6-8 2017 at the CityCube in Berlin.
News
APG has received an EU grant by the PERMIDES initiative to establish an in silico drug discovery platform.
Pipeline
We have currently two drug discovery programs: Huntington's disease and a transcription factor inhibitor for cancer treatment.
EIT Health Germany funds six promising start-ups with innovative solutions for healthcare and disease control
